FindTrial
Sign In

Correlation study of NAT2 gene polymorphism liver damage caused by anti-tuberculosis drugs

Correlation study of NAT2 gene polymorphism liver damage caused by anti-tuberculosis drugs

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300075322
Enrollment
Unknown
Registered
2023-09-01
Start date
2022-11-20
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tuberculosis

Interventions

Liver damage group:N/A
No liver damage group:N/A

Sponsors

Affiliated Hospital of Zunyi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: The patient met the national industry standard for tuberculosis diagnosis and was treated with isoniazid+rifampicin+ethambutol+pyrazinamide according to the tuberculosis treatment guidelines; At the same time, it meets the diagnostic criteria of drug-induced liver injury in the anti tuberculosis drug liver injury guidelines.

Exclusion criteria

Exclusion criteria: Complicated with viral hepatitis, liver tuberculosis, alcoholic liver disease, autoimmune hepatitis, fatty liver, or other liver damaging drugs, as well as cognitive impairment or refusal to participate in this study.

Design outcomes

Primary

MeasureTime frame
NAT2 genotype;—

Secondary

MeasureTime frame
Blood concentration;—

Countries

China

Contacts

Public ContactZong Zhaojing

Affiliated Hospital of Zunyi Medical University

zongzhaojing@qq.com+86 189 8522 9907

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026